Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

InMed Pharmaceuticals Inc INM

InMed Pharmaceuticals Inc. is a pharmaceutical company. It develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharmaceuticals segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is cannabinoid analog being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a cannabinol topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.


NDAQ:INM - Post by User

Bullboard Posts
Comment by Moneymagnet14on Mar 03, 2015 1:17am
49 Views
Post# 23482915

RE:InMed Expands Bod

RE:InMed Expands Bod Dr. Mansour was previously with Xenon Pharmaceuticals as its executive vice-president. He also held similar positions at Pfizer and Wyeth Pharmaceuticals, prior to founding Sabila Biosciences LLC, where he is currently the chief executive officer. Mr. Puil is currently a managing partner at a private equity fund based in California. Prior to that, he held senior positions at several firms including Bolder Investment Partners in Vancouver (now Haywood Securities), where he was a partner and portfolio manager; and in San Francisco at Gissen & Associates as portfolio manager, and the Encompass Fund as senior analyst. He currently serves as a board director of two Toronto Stock Exchange companies. He holds a degree in economics from the University of Victoria in British Columbia and is a chartered financial analyst charterholder.
Bullboard Posts